Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the companyâs transformative, high precision ophthalmic delivery platform. Eyenoviaâs pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases. Source
No articles found.
BIOLASE, Inc. is a medical device company and global market leader in the manufact...
BIOLASE, Inc. is a medical device company and g...
We are a patient-centric, clinical-stage biopharmaceutical company dedicated to br...
We are a patient-centric, clinical-stage biopha...
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focu...
Strongbridge Biopharma is a global commercial-s...
Since Aclaris was founded in 2012, our focus has been innovation to help people wi...
Since Aclaris was founded in 2012, our focus ha...
We are a profitable and growing company focused on the acquisition, development an...
We are a profitable and growing company focused...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.